| Antimicrobial Agent | Susceptibility Profile | Clinical Interpretation |
|---|---|---|
| Amikacin | Intermediate | 32 |
| Cefepime | Intermediate | 16 |
| Ceftazidime | Resistant | >=64 |
| Ciprofloxacin | Intermediate | 2 |
| Colistin | Resistant | >=16 |
| Gentamicin | Resistant | >=16 |
| Imipenem | Resistant | 8 |
| Levofloxacin | Intermediate | 4 |
| Meropenem | Resistant | >=16 |
| Minocycline | Sensitive | <=0.5 |
| Piperacillin/Tazobactam | Resistant | >=128 |
| Trimethoprim/Sulfamethoxazole | Resistant | >=320 |
| Resistant Gene Track | Detection Methodology | NCBI Genome Accession |
|---|---|---|
| blaoxa23-like | PCR | |
| blaoxa51-like | PCR |